Breakdown | |||||
TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
206.45M | 204.66M | 191.76M | 157.06M | 126.18M | 118.33M | Gross Profit |
47.31M | 137.16M | 28.81M | 25.98M | 20.57M | 19.26M | EBIT |
47.11M | 12.36M | 6.89M | 7.95M | 8.21M | 7.66M | EBITDA |
19.56M | 23.52M | 17.11M | 16.31M | 14.64M | 13.72M | Net Income Common Stockholders |
127.00K | 4.93M | 2.28M | 4.64M | 5.08M | 4.17M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
2.45M | 1.76M | 3.17M | 2.85M | 2.15M | 2.51M | Total Assets |
140.25M | 255.78M | 246.04M | 199.18M | 157.28M | 141.67M | Total Debt |
51.63M | 101.78M | 98.03M | 63.39M | 55.04M | 51.10M | Net Debt |
49.18M | 100.02M | 94.86M | 60.55M | 52.89M | 48.59M | Total Liabilities |
73.64M | 133.75M | 128.14M | 90.49M | 76.46M | 73.23M | Stockholders Equity |
65.74M | 122.02M | 117.87M | 108.55M | 79.81M | 67.41M |
Cash Flow | Free Cash Flow | ||||
13.31M | 14.01M | 9.25M | 10.21M | 8.71M | 5.52M | Operating Cash Flow |
19.18M | 18.88M | 17.45M | 15.08M | 13.69M | 7.51M | Investing Cash Flow |
-6.17M | -10.91M | -40.62M | -32.49M | -16.56M | -14.86M | Financing Cash Flow |
-12.42M | -9.39M | 23.49M | 18.11M | 2.51M | 7.99M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
64 Neutral | AU$74.50M | 506.25 | 0.11% | 4.94% | 2.00% | -94.63% | |
62 Neutral | $6.84B | 11.41 | 2.80% | 3.87% | 2.70% | -24.58% | |
$76.28B | 26.67 | 15.38% | 1.85% | ― | ― | ||
$1.46B | ― | -21.31% | ― | ― | ― | ||
$5.63B | 1,072.73 | 0.52% | 2.23% | ― | ― | ||
72 Outperform | AU$12.68B | 23.17 | 6.86% | 4.05% | 10.15% | 6.20% |
Apiam Animal Health Limited has announced a leadership transition with the departure of Dr. Chris Richards as CEO and Managing Director after over nine years. Bruce Dixon, a non-executive director with a proven track record in profitable growth, will serve as Interim Managing Director while the company searches for a new CEO. The transition aims to maintain focus on revenue opportunities and operational efficiencies within Apiam’s clinic portfolio, signaling a strategic shift in leadership to support continued growth and development.
The most recent analyst rating on (AU:AHX) stock is a Buy with a A$0.63 price target. To see the full list of analyst forecasts on Apiam Animal Health Ltd. stock, see the AU:AHX Stock Forecast page.
Apiam Animal Health Ltd. reported resilient financial results for the fiscal year 2025 to date, despite challenges in the equine market and reduced export diagnostic testing revenues. The company has divested two underperforming clinics to improve EBIT and is rolling out CoVet, an AI-driven clinical tool, to enhance efficiency and customer experience across its network. This strategic move is expected to streamline workflows, increase clinic capacity, and improve both employee and customer satisfaction, positioning Apiam favorably in the veterinary services industry.
Apiam Animal Health Ltd. announced the issuance of 128,671 performance rights as part of an employee incentive scheme. These securities are unquoted and are not intended to be listed on the ASX, reflecting the company’s strategy to reward and retain its workforce, potentially impacting its operational efficiency and stakeholder engagement.
Apiam Animal Health Ltd. announced the application for the quotation of 1,420,737 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of a dividend or distribution plan, potentially impacting the company’s financial structure and providing additional liquidity options for stakeholders.
Apiam Animal Health Ltd. announced a change in the director’s interest, with Christopher Richards acquiring 112,406 fully paid ordinary shares, bringing his total to 43,386,270 shares. This acquisition, conducted through a market purchase, reflects a strategic move that could potentially impact the company’s market positioning and stakeholder confidence.
Apiam Animal Health Ltd. has announced an update regarding the issue price of shares for shareholders participating in the Dividend Reinvestment Plan for the H1 FY2025 Interim Dividend. This update clarifies the financial arrangements for shareholders, potentially impacting their investment decisions and reflecting the company’s ongoing commitment to shareholder value.